Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ... [Yahoo! Finance]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Operating Expenses : R&D expenses were $13.4 million in Q4, with a total of $49.9 million for the year. Cash Position : PHAT ended the year with $381.4 million in cash and cash equivalents. Non-GAAP Adjustments : Non-GAAP adjusted net loss was $45.9 million for Q4 and $129.7 million for the full year. Stock-Based Compensation : Included in the non-GAAP adjustments, stock-based compensation expense was $24.6 million for Q4. Warning! GuruFocus has detected 3 Warning Signs with PHAT. On March 7, 2024, Phathom Pharmaceuticals Inc ( NASDAQ:PHAT ) released its 8-K filing , detailing the financial results for the fourth quarter and the full year ended December 31, 2023. The company, known for its focus on developing novel treatments for gastrointestinal diseases, has recently launched VOQUEZNA, a new class of treatment for Erosive GERD, marking a significant milestone in its commercial endeavors. Financial Performance and Business Highlights Phathom Pharmaceuticals reported it
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024GlobeNewswire
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCTPR Newswire
- SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCTPR Newswire
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
PHAT
Earnings
- 3/7/24 - Miss
PHAT
Sec Filings
- 4/12/24 - Form DEFA14A
- 4/12/24 - Form DEF
- 4/12/24 - Form ARS
- PHAT's page on the SEC website